We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
+130.68%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$355M
AUM Growth
+$103M
Cap. Flow
+$153M
Cap. Flow %
42.91%
Top 10 Hldgs %
59.98%
Holding
61
New
22
Increased
9
Reduced
5
Closed
10

Top Buys

Rank Stock Value
1
ICLR icon
Icon
ICLR
+$45.7M
2
CI icon
Cigna
CI
+$22.8M
3
QTTB icon
Q32 Bio
QTTB
+$22M
4
SNY icon
Sanofi
SNY
+$19.7M
5
MMS icon
Maximus
MMS
+$18.5M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$24.3M
2
LH icon
Labcorp
LH
+$13.8M
3
KVUE icon
Kenvue
KVUE
+$11M
4
BDSX icon
Biodesix
BDSX
+$7.72M
5
RLAY icon
Relay Therapeutics
RLAY
+$6.7M

Sector Composition

Rank Sector Weight
1 Healthcare 91.96%
2 Industrials 8.01%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
26
Ironwood Pharmaceuticals
IRWD
$709M
$4.02M 1.13%
+907,783
New +$3.68M
AORT icon
27
Artivion
AORT
$1.33B
$3.46M 0.97%
121,178
– –
ERAS icon
28
Erasca
ERAS
$6.19B
$3.4M 0.96%
1,356,186
-863,000
-39% -$2.37M
TYRA icon
29
Tyra Biosciences
TYRA
$1.93B
$3.35M 0.94%
240,870
-160,000
-40% -$2.9M
IDYA icon
30
IDEAYA Biosciences
IDYA
$3.41B
$3.16M 0.89%
123,000
– –
ACOG
31
Alpha Cognition
ACOG
$184M
$2.56M 0.72%
+434,700
New +$2.44M
QTTB icon
32
Q32 Bio
QTTB
$451M
$2.4M 0.68%
+697,413
New +$22M
TELA icon
33
TELA Bio
TELA
$33.1M
$1.9M 0.54%
+630,000
New +$1.77M
NUVB icon
34
Nuvation Bio
NUVB
$2.14B
$1.78M 0.5%
668,115
– –
CNTX icon
35
Context Therapeutics
CNTX
$55.5M
$1.39M 0.39%
1,328,352
– –
ALEC icon
36
Alector
ALEC
$168M
$1.16M 0.33%
+615,628
New +$2.32M
ENTA icon
37
Enanta Pharmaceuticals
ENTA
$377M
$1.02M 0.29%
177,004
– –
OVID icon
38
Ovid Therapeutics
OVID
$435M
$934K 0.26%
+1,000,000
New +$1.12M
APRE icon
39
Aprea Therapeutics
APRE
$7.4M
$910K 0.26%
276,603
– –
FHTX icon
40
Foghorn Therapeutics
FHTX
$271M
$574K 0.16%
121,672
– –
CCCC icon
41
C4 Therapeutics
CCCC
$387M
$558K 0.16%
+155,000
New +$771K
AVTX icon
42
Avalo Therapeutics
AVTX
$955M
$531K 0.15%
71,458
– –
BOLD
43
Boundless Bio
BOLD
$57.8M
$470K 0.13%
162,058
– –
NYXH
44
Nyxoah
NYXH
$146M
$407K 0.11%
50,839
– –
MODD icon
45
Modular Medical
MODD
$12M
$345K 0.1%
8,400
+4,374
+109% +$254K
MESO
46
Mesoblast
MESO
$1.88B
$230K 0.06%
+11,600
New +$128K
NXTC icon
47
NextCure
NXTC
$23.5M
$100K 0.03%
10,833
– –
HUMAW icon
48
Humacyte Inc Warrant
HUMAW
$1.07M
$91.7K 0.03%
49,998
– –
TERN
49
DELISTED
Terns Pharmaceuticals
TERN
$55.4K 0.02%
10,000
– –
RCKTW icon
50
Rocket Pharmaceuticals Warrant
RCKTW
$192K
$15.4K ﹤0.01%
400,000
– –
1
2
3

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return

Sio Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Sio Capital Management held 61 positions worth $355M, up 41% from $252M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sio Capital Management deployed $153M of net new capital in Q4 2024, opening 22 new positions and adding to 9 existing holdings. Its largest new stake was Icon: 195,500 shares worth $41M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 78% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Labcorp, an estimated $13.8M trimmed.

  • Sio Capital Management's largest Q4 2024 buy was Icon: 195,500 shares worth $41M.
  • Sio Capital Management added most to Cigna in Q4 2024, an estimated $22.8M increase.
  • Sio Capital Management's biggest Q4 2024 reduction was Labcorp, cutting an estimated $13.8M.
  • Sio Capital Management fully exited Teva Pharmaceuticals in Q4 2024, selling an estimated $24.3M.
  • Sio Capital Management's ten largest holdings make up 60% of its $355M portfolio in Q4 2024.
  • Sio Capital Management opened 22 new positions and closed 10 in Q4 2024.
  • Sio Capital Management's portfolio value rose 41% quarter-over-quarter to $355M.

Based on Sio Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.